Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation

Here, the efficacy of abatacept in patients with early diffuse systemic sclerosis (dcSSc) was analyzed to test the hypothesis that patients in the inflammatory intrinsic subset would show the most significant clinical improvement. Eighty-four participants with dcSSc were randomized to receive abatac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Bhaven K., Espinoza, Monica E., Franks, Jennifer M., Yuan, Yiwei, Wang, Yue, Wood, Tammara, Gudjonsson, Johann E., Spino, Cathie, Fox, David A., Khanna, Dinesh, Whitfield, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869963/
https://www.ncbi.nlm.nih.gov/pubmed/36355434
http://dx.doi.org/10.1172/jci.insight.155282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869963/
https://www.ncbi.nlm.nih.gov/pubmed/36355434
http://dx.doi.org/10.1172/jci.insight.155282

Ejemplares similares